Ampli®cation and/or overexpression of the receptor tyrosine kinase HER2/Neu and the cell cycle regulatory gene cyclin D1 are frequently associated with human breast cancer. We studied the functional signi®cance of cyclin D1 in Neu-induced mammary oncogenesis by developing mice overexpressing either wild-type or mutant Neu in a cyclin D1 de®cient background. The absence of cyclin D1 suppresses mammary tumor formation induced by the wild-type or activated mutant form of Neu, which promote multi-and single-step progression of tumorigenesis, respectively. These data indicate that cyclin D1 is preferentially required for Neumediated signal transduction pathways in mammary oncogenesis. Signi®cantly, 35% of mutant Neu/cyclin D1 7/7 mice regained mammary tumor potential due to compensation by cyclin E. Thus, shared targets of cyclins D1 and E are important in modulating Neu function in mammary tumorigenesis. Our results imply that the combinatorial inhibition of cyclins D1 and E might be useful in the treatment of malignancies induced by Neu.
Introduction
The human homologue of Neu (c-erbB-2 or HER2), a member of the epidermal growth factor receptor family, is ampli®ed and/or overexpressed in 20 ± 45% of human mammary cancers and is associated with poor prognosis (Andrulis et al., 1998; Briscoe et al., 1993; Press et al., 1993; Slamon et al., 1987 Slamon et al., , 1989 . To model human breast cancer in mice, an erbB-2 transgene was expressed under the regulatory control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR). This promoter/enhancer is mammary tissue-speci®c and transgenic mice expressing the proto-oncogene Neu display a multi-step development of mammary adenocarcinoma with high potential for metastasis (Guy et al., 1992) . Although low levels of Neu expression in the mammary epithelium do not initially aect mammary gland function or development, after several months focal tumors appear, surrounded by hyperplastic and normal mammary epithelium. Therefore, Neu is necessary but not sucient for tumor formation, requiring other genetic events for this process to take place (Guy et al., 1992) .
Activated c-neu is generated by a single amino acid substitution in the transmembrane domain of the Neu protein (Bargmann et al., 1986) which results in activation of a transforming tyrosine kinase (Bargmann and Weinberg, 1988; Stern et al., 1988; Weiner et al., 1989a) by inducing ligandindependent oligomerization (Weiner et al., 1989b) . Overexpression of activated c-neu in transgenic mice induces mammary adenocarcinomas that are synchronous and polyclonal in origin, indicating that activated c-neu is sucient to induce malignant transformation in mammary epithelial cells in a single step (Muller et al., 1988) .
Activation of the Neu signal transduction pathway results in the initiation of homo-and heterodimers with other members of Erb family (PinkasKramarski et al., 1996) , leading to autophosphorylation and initiating a downstream cascade of events that include ras activation (Janes et al., 1994) . This subsequently activates the MAPK signaling pathway, including extracellular mitogenic signaling mediators p42 and p44 (ERK1 and 2) (Amundadottir and Leder, 1998) . Upon stimulation by extracellular signals, this pathway promotes cellular proliferation initiating with the G1 phase of the cell cycle (Albanese et al., 1995) . Two distinct classes of cyclins are expressed in mammalian cells during the G1 phase of the cell cycle: D-type cyclins (cyclins D1, D2, and D3) and cyclin E (Sherr, 1993) . Cyclin D1, in particular, is a critical target for proliferative signals in the G1 phase and its overexpression/ association with CDK4/6 initiates cell cycle progression by phosphorylating the retinoblastoma protein (pRb). A subsequent phosphorylation of pRb by the cyclin E/CDK2 complex during late G1 phase promotes progression to the S phase of the cell cycle (Sherr, 1993 (Sherr, , 1994 .
Cyclin D1 is ampli®ed in approximately 30% and overexpressed in 60 ± 80% of breast cancers in correlation with poor prognosis and the presence of lymph node metastases (Barnes and Gillett, 1998) . Transgenic mice overexpressing cyclin D1 from the mouse mammary tumor virus (MMTV) promoter develop breast carcinomas (Wang et al., 1994) . In contrast, the mammary glands of virgin female mice lacking cyclin D1 appear to be normal, but ductal side branching and lobuloalveolar development associated with pregnancy are severely impaired, resulting in their inability to breast feed (Fantl et al., 1995; Sicinski et al., 1995) . These data suggest a speci®c role for cyclin D1 in mammary development and cancer.
Recent data demonstrates that cyclin D1 is a critical target of Neu-induced transformation (Lee et al., 2000) . The receptor tyrosine kinase, Neu, has been linked to signal transduction pathways involving ras (Janes et al., 1994; Kurebayashi, 2001) . Several lines of evidence indicate that the cyclin D1-CDK4/6-pRb regulatory circuit lies downstream of oncogenic ras (Filmus et al., 1994; Peeper et al., 1997; Serrano et al., 1995) . Data from human cancers also indicate that cyclin D1 mediates the proliferative response to oncogenic ras (Serrano et al., 1995) . However, the essential role of cyclin D1 as a mediator of mammary epithelial transformation in vivo by oncogenic Neu has not been fully investigated. It is expected that inactivation of the cyclin D1-CDK4/6-pRb pathway by deletion of the cyclin D1 gene may suppress mammary tumor development in MMTV-Neu (wild-type or mutant) transgenic mice. Here we validate these expectations and study the modulation of G1 cyclins in secondary genetic changes that can either reinstate or suppress mammary tumorigenesis.
We studied the functional role of cyclin D1 in the initiation and progression of Neu-induced mammary carcinogenesis using the following in vivo systems: mice carrying MMTV wild-type (unactivated) Neu (Neu wt ) and mice carrying MMTV mutant (activated) c-neu (neu mut ), each with cyclin D1 wild-type or de®cient genetic background. Analysis of transgenic and bitransgenic mice indicates that the absence of cyclin D1 has a dramatic eect on Neu-induced mammary tumor development, suppressing both multi-and single-step induction of mammary gland tumors in Neu wt and neu mut transgenic mice, respectively. However, 35% of cyclin D1 de®cient neu mut transgenic mice regained tumor potential following a prolonged latency period. We propose possible mechanisms contributing to antiproliferative eects related to the absence of cyclin D1 in Neu-mediated mammary tumorigenesis, and the relation of these eects to the Neu signaling pathway. The modulation of dierent G1 cyclins is thus implicated in molecular mechanisms which allow neu mut transgenic mice to escape the anti-proliferative eects of the cyclin D1 de®ciency. females develop mammary tumors after a prolonged latency period (at an average of 16 months of age) ( Figure 1b ). Mammary gland tumors were not detected in the greater proportion (65%) of neu mut / cyclin D1 7/7 female mice (examined for up to 2 years) (Figure 1b) .
Results

Susceptibility of
Deficiency of cyclin D1 ablates or delays the severity of oncogenic changes in mammary gland morphology of Neu wt or neu mut mice
To determine the in¯uence of cyclin D1 deletion on mammary glands from Neu wt and neu mut transgenic mice, we performed whole mount analysis and histopathological evaluation to analyse ductal morphology and the de®ned stage of tumorigenesis for the dierent genotypes. The mammary ductal tree from Neu wt or neu mut mice, wild-type or heterozygous for cyclin D1, demonstrate hyperplastic and dysplastic changes, consisting of intraductal and lobular lesions ( Figure 2e ,f and i,j). Solid mammary carcinomas are also observed. However, the absence of cyclin D1 in Neu wt or neu mut mammary glands markedly reduces hyperplastic and dysplastic lesions, as evaluated by whole mount and histopathological analysis ( Figure 2g ,h and k,l). Thus, morphological evidence suggests that de®ciency of cyclin D1 maintains suppression of 100% of multi-step mammary oncogenesis in Neu wt mice and 65% of single-step mammary oncogenesis in neu mut mice for up to 24 months of age. Mammary morphology appears normal in these mice, except for the degree of ductal branching and dilation, which is slightly increased by comparison to mammary glands from non-transgenic mice of the same age. In the 35% of neu mut /cyclin D1 7/7 mice that develop mammary tumors following a prolonged latency period, the mammary architecture appears normal in a majority of the tissue. However, very few regions of intraductal and lobular lesions are present (Figure 2m ,n). In contrast, multifocal lesions develop in the entire mammary tissue of neu mut /cyclin D1 +/+ or +/7 mice ( Figure 2j ).
Neu-induced mammary tumors have altered expression patterns of D-type cyclins in the presence and absence of cyclin D1
Overexpression of Neu wt is known to alter control of cellular proliferation. Recent studies show that cyclin D1 expression is increased in mammary tumors and breast cancer cell lines in correlation with induction of transforming Neu (Lee et al., 2000) . To further assess the role of D-type cyclins in mammary glands of Neu wt or neu mut mice, we performed Northern blot analysis to determine RNA levels of cyclins D1, D2, and D3. We observed that cyclin D1 is overexpressed, cyclin D2 is markedly reduced, and cyclin D3 levels are unchanged, in comparison to mammary gland tissue from nontransgenic mice (Figure 3a ). Changes in cyclin D1 levels correlate with increased levels of Neu (Figure 3a ). These data indicate that cyclin D1 is a preferential target for both the wild-type and mutant forms of Neu. Observation of a dramatic reduction of cyclin D2 in both Neu wt and neu mut mammary gland tumors (currently under investigation) is consistent with recent studies demonstrating that loss of cyclin D2 expression is associated with human breast cancer evolution (Evron et al., 2001 ).
Next we studied expression of G1 cyclins in Neu wt and neu mut mice with D1 de®cient background. Northern blot analysis using total RNA derived from either Neu wt /cyclin D1 7/7 or neu mut /cyclin D1 7/7 mice shows no detectable expression of cyclin D1, and no signi®cant change in either cyclin D2 or cyclin D3 expression in comparison to non-transgenic control animals ( Figure  3b ). These results demonstrate that neither cyclin D2 nor D3 compensate for the absence of cyclin D1 to promote the oncogenic potential of Neu. neu mut bypasses cyclin D1 dependency to induce mammary tumorigenesis Our next goal was to distinguish between the biological properties of mammary tissue derived from tumor bearing versus tumor-free neu mut /cyclin D1 7/7 mice. Thirty-®ve per cent of older neu mut mice display phenotypic changes indicative of dysplastic mammary gland lesions. This indicates the presence of a mechanism that may override the functional replacement of cyclin D1 by other G1 cyclins. Northern blot analysis of mammary tumor tissue from neu mut /cyclin D1 7/7 mice demonstrates that cyclin D1 is undetectable, cyclin D2 is down-regulated, and cyclin D3 levels remain unchanged (Figure 3c) . Cyclin E mRNA and protein are upregulated in neu mut mammary gland tumor tissues derived from cyclin D1 de®cient mice, but not in the 65% of tumor-free mice bearing the same genotype, suggesting that cyclin E may compensate for the loss of cyclin D1 in cell proliferation (Figure 4a and b) .
To further assess the functional role of cyclin E, we analysed its association with kinase partner CDK2, as well as its alternative associative properties with cyclin D-speci®c partner CDK4. Immunoprecipitation of cyclin E from mammary gland lysates demonstrates a strong increase in association levels of cyclin E with CDK2 in neu mut and neu mut /cyclin D1 7/7 tumors, by comparison to neu mut /cyclin D1 7/7 tumor free and nontransgenic mammary tissue (Figure 4c ). In addition, immunoprecipitation of cyclin E demonstrates low levels of association with CDK4 in mammary tissue from all genetic categories studied (Figure 4c ). Interestingly, the association of cyclin E with CDK4 is reduced in the presence of cyclin D1. This reduction corresponds with increased association of cyclin D1 with CDK4 (Figure 4c ). Both cyclin D/CDK4 and cyclin E/CDK2 active complexes regulate the G1 phase of the cell cycle by phosphorylating a common target, the retinoblastoma protein (pRb) (Sherr and Roberts, 1995) . Therefore, we analysed levels of pRb and phosphorylated pRb (P-pRb) in mammary gland lysates from neu mut transgenic mice in the presence and absence of cyclin D1, and in non-transgenic mice wild-type or de®cient for cyclin D1. In mammary glands from neu mut mice, induction of cyclin D1 coincides with a strong increase of the hyperphos-phorylated forms of pRb, as shown using an antibody speci®c to the P-pRb ( Figure  4d ). In the absence of cyclin D1 from mammary glands /cyclin D1 7/7 (~; n=22) mice. Mice were monitored for mammary adenocarcinomas for up to 2 years of age of neu mut tumor-free mice, expression levels for pRb and P-pRb are similar to or lower than non-transgenic mice wild-type for cyclin D1 (Figure 4d ). In contrast, mammary glands from neu mut /cyclin D1 7/7 mice bearing tumors demonstrate a marked increase in P-pRb (Figure 4d ). Taken together, these data indicate that pRb undergoes hyperphosphorylation in the absence of cyclin D1, likely via compensation by the cyclin E/CDK2 complex.
Deficiency of cyclin D1 suppresses Neu-mediated tumorigenicity which is correlated with reduction of Neu levels and MAPK activity It has been shown that Neu activates the ras-MAPK signaling pathway (Janes et al., 1994; Kurebayashi, 2001 ). We therefore extended our studies to demonstrate that Neu-induced overexpression of cyclin D1 is correlated with the ras-MAPK signaling pathway. We demonstrate that the MAPK activity generated by mammary tumor tissue from Neu wt and neu mut transgenic mice is increased by 5 ± 10-fold in comparison to mammary tissue from nontransgenic mice (Figure 5a ). In the absence of cyclin D1, we observed a signi®cant reduction in the phosphorylation of p42/p44 MAPK (Figure 5a ) as well as reduced levels of Neu protein (Figure 5b ) in mammary epithelium derived from Neu wt or neu mut transgenic mice. These ®ndings likely result from a reduction in cell proliferation in the absence of cyclin D1. Neu-induced mitogenesis appears to be severely impaired in the absence of cyclin D1.
Discussion
Overexpression of HER2/Neu in breast cancer is associated with aggressive tumor phenotypes and poor patient prognosis. Therefore, understanding the molecular mechanisms by which Neu overexpression potentiates tumor cell growth is an important objective for the generation of new therapies to treat human breast cancer.
Our data indicate that the Neu oncogene, a homologue of the human HER2/Neu gene implicated in the majority of breast cancers, acts preferentially through cyclin D1 to evoke its carcinogenic eects in the breast. We utilized cyclin D1-de®cient mice to test whether cyclin D1 is an essential mediator for oncogenic Neu in mammary tumorigenesis, in vivo. Our results demonstrate remarkable suppression of mammary tumor formation in mice carrying either Neu wt or neu mut and de®cient for cyclin D1. Cyclin D1 7/7 mice bearing Neu wt display a 100% reduction in multi-step mammary tumorigenesis compared to mice possessing the Neu wt transgene alone. In addition, cyclin D1 de®cient mice carrying neu mut display a 65% decrease in single-step mammary tumorigenesis compared to neu mut /cyclin D1 +/+ mice. At least three possible models may explain the observed reduction in Neu-induced mammary tumorigenesis in cyclin D1 de®cient mice. A theoretical possibility is that the observed reduction in tumor formation is due to a loss of epithelial cells expressing the MMTV-oncogene. Results from our work and others make this scenario unlikely. Mammary glands in cyclin D1 de®cient mice are histologically normal, comparable to virgin wild-type females, and phenotypic mammary gland defects caused by cyclin D1 de®ciency are pregnancy-associated (Fantl et al., 1995; Sicinski et al., 1995) .
Lobuloalveolar development comparable to pregnant non-transgenic wild-type females occurs in virgin Figure 2 Morphological eects of the absence of cyclin D1 in Neu wt or neu mut -induced mammary tumorigenesis. Representative whole mounts (top panels) and hematoxylin and eosin (H&E) sections (bottom panels) of the left thoracic mammary gland harvested from a,b non-transgenic control (6 months old), c,d cyclin D1
7/7 (6 months old), e,f Neu wt (10 months old), g,h Neu wt /cyclin D1 7/7 (20 months) and i,j neu mut (7 months old), k,l neu mut /cyclin D1 7/7 tumor-free (14 months old) and m,n neu mut / cyclin D1 7/7 tumor bearing (T) (14 months old) mammary gland sections. Results represent observation of 20 mammary glands from 10 mice of each genotype MMTV-wnt-1 mice (Tsukamoto et al., 1988) independent of cyclin D1 genotype (Yu et al., 2001) , further demonstrating that cells expressing the MMTV-oncogene are not eliminated by cyclin D1 de®ciency. Furthermore, MMTV-myc and MMTV-wnt-1 and MMTV-neu mut mice induce mammary gland tumors in cyclin D1 de®cient mice (Yu et al., 2001 and Figure  2 ). Tumors would not form in these mice if the MMTV-oncogene expressing cells were not viable in the absence of cyclin D1.
A second model is that cyclin D1 modulates the MMTV promoter, and that in the absence of cyclin D1, the transgene is not expressed. This is not a likely possibility based on recent experimental evidence generated by us and others. Dierent oncogenes have been found to be expressed from the MMTV promoter independently of cyclin D1 status. Speci®cally, it has been demonstrated that expression of a MMTV-c-myc or -wnt-1 transgene induces mammary tumor development in cyclin D1 wild-type or de®cient mice (Yu et al., 2001 ). In addition, data from this manuscript (Figure 5b) , and a recent publication (Yu et al., 2001) , indicate that epithelial cells express the MMTV-transgene independently of cyclin D1 genotype. Expression levels of MMTV-v-Ha-ras and MMTV-neu mut in mammary glands of cyclin D1 de®cient mice are similar to their expression in cyclin D1 wild-type mice (Yu et al., 2001 ). Although we found reduced amounts of Neu protein in mammary tissue from Neu wt or neu mut /cyclin D1 de®cient mice in comparison to Neu wt or neu mut /cyclin D1 wildtype mice, these reduced levels likely re¯ect the lack of tumors and/or hyperplasia. Thus, the ability of multiple transgenes to be expressed from the MMTV promoter in the absence of cyclin D1 has been demonstrated. However, the MMTV promoter may be less active in the absence of cyclin D1. The observed suppression of Neu-induced mammary carcinogenesis compared to the lack of suppression of myc or wnt-1-induced oncogenesis could thus re¯ect a dierent threshold required for tumor formation by these various oncogenes.
The third model is that cyclin D1 is preferentially required for Neu-mediated oncogenic signal transduction. We favor this model and also show that the absence of cyclin D1 cannot be compensated for by cyclins D2 or D3, resulting in the dramatic suppression of both Neu expression and mammary tumor formation.
Our ®ndings are supported by previous xenograft studies, demonstrating that cell lines transfected with wild-type or oncogenic HER2/Neu have elevated expression of cyclin D1 protein. Transfection of antisense cyclin D1 into activated Neu-transformed mammary cells inhibits S phase entry, while blocking growth of these cells in immunode®cient mice (Lee et al., 2000) . Recent data from Yu et al. (2001) con®rm the importance of cyclin D1 in Neu-ras oncogenic signaling. However, the results presented here also show that a signi®cant percentage of neu mut /cyclin D1 7/ 7 mice form mammary gland tumors following a long latency period.
Our studies suggest an alternative signaling pathway that permits neu mut -induced tumorigenesis to escape cyclin D1 dependency. We found that in the 35% of neu mut /cyclin D1 7/7 mice that regain tumorigenic potential after a prolonged latency period, neu mut cannot exert its oncogenic eects through either of the two other D-type cyclins as expression of cyclin D2 is down-regulated and cyclin D3 is unchanged ( Figure  3c ). However, in this percentage of neu mut /cyclin D1 7/7 mice in which tumorigenicity is restored, we found that cyclin E is overexpressed and forms a complex with CDK2, and may thus compensate for loss of cyclin D/ CDK4. These data suggest that cyclin E mediates neu mut -induced mammary carcinogenesis in a cyclin D1-independent manner. Furthermore, our results show that the cyclin E/CDK2 complex is capable of phosphorylating pRb to promote mammary tumor growth in neu mut /cyclin D1 7/7 mice. These observations are consistent with other studies that demonstrate a strong correlation between inappropriate cyclin E expression and human breast cancer 7/7 lanes probed for cyclin D1 is due to background hybridization, consistent with absence of cyclin D1 as determined via PCR and Western blot analyses.) Ethidium bromide staining of the 28s rRNA from each blot is shown (Gray-Bablin et al., 1996; Keyomarsi et al., 1994) . In addition, cyclin E induces mammary gland hyperplasia and carcinomas in transgenic mice when expressed under the control of the MMTV promoter (Bortner and Rosenberg, 1997 ). Sicinski and co-workers (1995) have generated cyclin E?D1`knock-in' mice in which the cyclin D1 coding sequence is substituted for by that of cyclin E (Geng et al., 1999) . Using these mice they have shown that critical functions of the cyclin D1/ CDK4 complex can be replaced by cyclin E/CDK2, both in normal mammary gland development (Geng et al., 1999) and neu mut -induced mammary oncogenesis (Yu et al., 2001) . These studies provide genetic evidence that cyclin E can ful®ll at least some of the functions normally performed by cyclin D1 in cell cycle progression during development and cancer.
The Neu-ras-MAPK-cyclin D1 signaling pathway is involved in a wide spectrum of human epithelial cancers. Our research contributes new insight into the role of cyclin D1 in the suppression of the oncogenic Neu signaling pathway. Moreover, our data con®rms an escape pathway occurring via cyclin E in cyclin D1 independent neu mut mammary oncogenesis, which may be implicated in the relapse of HER2/Neu-positive breast cancers. Thus understanding the modulation of cyclins D1 and E in Neu-induced oncogenesis may prove valuable in the development of combinationtherapies for the clinical treatment of breast and other epithelial cancers.
Materials and methods
Generation of mice
Transgenic mice that express the Neu proto-oncogene (unactivated) (Neu wt ) (Guy et al., 1992) or c-neu (activated) (neu mut ) transgene (Muller et al., 1988) in the mammary gland under the MMTV promoter were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and Charles River Laboratories (Wilmington, MA, USA), respectively. Mice heterozygous for cyclin D1 (Sicinski et al., 1995) , cyclin D1 +/+ . At least 20 virgin female mice in each category were maintained for up to 2 years of age while being monitored twice weekly for tumors. Females that developed mammary gland tumors were sacri®ced when tumors reached 42 cm in diameter.
Histopathology
Mammary tissue was dissected from adult mice, ®xed in 4% paraformaldehyde and embedded in paran. Sections were cut at 5 mm and stained with hematoxylin and eosin for histopathological evaluation by Experimental Pathology Laboratories, Inc. (Herndon, VA, USA).
Mammary gland whole mounts
The left inguinal and thoracic mammary glands were dissected, spread onto a glass slide, ®xed for 2 ± 4 h in Carnoy's ®xative (ethanol:chloroform:acetic acid 6 : 3 : 1), washed 15 min in 70% ethanol, washed 5 min in distilled water, and stained in 0.2% carmine/0.5% aluminum 
Northern blotting
Total RNA was extracted from frozen mammary tissue samples using RNA STAT-60 (Tel-Test, Friendswood, TX, USA) according to manufacturer's protocol. Samples (15 ug) were separated on a 1% agarose/formaldehyde gel, blotted to nitrocellulose membrane and hybridized with 32 P-labeled cDNAs. Mouse cyclin D1 cDNA was provided by P Sicinski (Harvard Medical School, Boston, MA, USA), murine cyclin D2 and murine cyclin D3 cDNAs were provided by C Sherr (St. Jude Children's Research Hospital, Memphis, TN, USA), murine cyclin E was provided by J DeLoia (University of Pittsburg, Pittsburg, PA, USA) and Neu cDNA was provided by W Muller (McMaster University, Hamilton, Ontario, Canada) . Hybridizations were performed with QuickHyb (Stratagene, La Jolla, CA, USA) followed by autoradiography.
Western blotting
Tissue samples were homogenized and lysed with RIPA buer containing protease inhibitors (16PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF) and cleared by centrifugation. Equal amounts of samples (50 ± 150 mg) were separated through 6, 8, 10, and 12% TrisGlycine gels, transferred to nitrocellulose membranes (Invitrogen, Carlesbad, CA, USA) and analysed according to the protocol by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Blots were probed with the following primary antibodies: mouse monoclonal antibodies against P-pRb/ pRb (G3-245, PharMingen, San Diego, CA, USA), Neu (Ab-3, Oncogene Research Products, Boston, MA, USA); and rabbit polyclonal antibodies against MAPK (V8031, Promega, Madison, WI, USA), P-pRb (9300, Cell Signaling Technology, Beverly, MA, USA), and Erk-2 (K-23), CDK2 (C-22), and CDK4 (M-2) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). As secondary antibody, appropriate peroxidase-conjugated anti-mouse (Santa Cruz Biotechnology) or anti-rabbit (Caltag Laboratories, Burlingame, CA, USA) was used, followed by enhanced chemiluminescence (ECL) detection (Pierce, Rockford, IL, USA).
Immunoprecipitation and protein association assays
Tissue samples were homogenized and lysed in buer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, and Complete EDTA-free protease inhibitor`cocktail' (Roche, Indianapolis, IN, USA). Immunoprecipitation was performed following the protocol from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Equal amounts of protein (1 mg) were incubated with anti-mouse cyclin E antibody (M-20) conjugated to agarose beads (Santa Cruz Biotechnology). Immunoprecipitate was separated on 10% Tris-Glycine gels and transferred to nitrocellulose membrane. Immunoblots were treated as described above. 
